



## STUDY PROTOCOL

# REVISED Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: a scoping review protocol [version 2; peer review: 2 approved]

Christian Appenzeller-Herzog <sup>1</sup>, Steffen Hartleif<sup>2</sup>, Julien Vionnet <sup>3-5</sup>

<sup>1</sup>University Medical Library, University of Basel, Basel, 4051, Switzerland

<sup>2</sup>University Hospital for Children and Adolescents Tübingen, University Hospital Tübingen, Stuttgart, 70597, Germany

<sup>3</sup>Institute of Liver Studies, King's College Hospital, London, London, UK

<sup>4</sup>Transplantation Centre, University of Lausanne, Lausanne, Switzerland

<sup>5</sup>Service of Gastroenterology and Hepatology, University of Lausanne, Lausanne, Switzerland

**v2** First published: 05 Dec 2019, 8:2059 (<https://doi.org/10.12688/f1000research.21501.1>)

Latest published: 29 Jan 2020, 8:2059 (<https://doi.org/10.12688/f1000research.21501.2>)

## Abstract

**Objective:** This scoping review aims at systematically mapping reported prognostic factors for spontaneous immunosuppression (IS) free allograft tolerance (operational tolerance, OT) in non-viral hepatitis and non-autoimmune disease liver transplant (LT) recipients who are undergoing immunosuppression withdrawal (ISW). The results may inform the subsequent conduct of a systematic review with a more specific review question.

**Background:** LT is currently the most effective treatment for end-stage liver diseases. Whereas the short-term outcomes after LT have dramatically improved over the last decades, the long-term outcomes remain unsatisfactory, mainly because of side effects of lifelong IS, such as infections, cardiovascular diseases, malignancies, and nephrotoxicity. ISW studies have shown that OT can be achieved by a subset of LT recipients and recent research has identified biomarkers of OT in these patients. However, an evidence-based selection algorithm for patients that can predictably benefit from ISW is not available to date. The planned review will, therefore, map existing knowledge on prognostic clinical parameters and biomarkers for OT.

**Inclusion criteria:** We will consider studies that record any clinical parameter or biomarker before the initiation of ISW in paediatric or adult non-viral hepatitis and non-autoimmune disease LT recipients and analyse their possible association with ISW outcomes (OT or non-tolerance). Studies addressing the effectiveness of OT-inducing treatments will be excluded.

**Methods:** Embase, MEDLINE, and Cochrane Library will be searched for relevant articles or conference abstracts. Full-texts of selected abstracts will be independently screened for inclusion by two reviewers. References and citing articles of included records will be screened for additional relevant records. Clinical trial registries will be searched for ongoing studies, and their investigators contacted for the sharing of unpublished data. Data from included records will be independently extracted by two reviewers using a

## Open Peer Review

Reviewer Status

|  | Invited Reviewers |        |
|--|-------------------|--------|
|  | 1                 | 2      |
| version 2<br>(revision)<br>29 Jan 2020 |                   | report |
|  | ↑                 |        |
| version 1<br>05 Dec 2019               |                   | report |

- 1 **Deirdre Kelly**, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK
- 2 **Piotr Czubowski** , The Children's Memorial Health Institute, Warsaw, Poland

Any reports and responses or comments on the article can be found at the end of the article.

prespecified data extraction table and presented in both tabular and narrative form.

### Keywords

biomarker, clinical parameter, flow cytometry, gene expression profiling, immunosuppression, immunosuppression withdrawal, liver biopsy, liver transplantation, operational tolerance, regulatory lymphocytes, scoping review, Tregs

**Corresponding author:** Christian Appenzeller-Herzog ([christian.appenzeller@unibas.ch](mailto:christian.appenzeller@unibas.ch))

**Author roles:** **Appenzeller-Herzog C:** Conceptualization, Investigation, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Hartleif S:** Writing – Review & Editing; **Vionnet J:** Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** JV is supported by the Swiss National Science Foundation (grant P2LAP3\_181318).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2020 Appenzeller-Herzog C *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Appenzeller-Herzog C, Hartleif S and Vionnet J. **Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: a scoping review protocol [version 2; peer review: 2 approved]** F1000Research 2020, 8:2059 (<https://doi.org/10.12688/f1000research.21501.2>)

**First published:** 05 Dec 2019, 8:2059 (<https://doi.org/10.12688/f1000research.21501.1>)

**REVISED Amendments from Version 1**

In version 2, we aimed to clarify three issues:

- i) The scoping review will include paediatric and adult patients
- ii) The scoping review will focus on studies on full IS withdrawal and exclude studies on IS minimisation
- iii) The primary objective of the scoping review will be to map all published prognostic factors for spontaneous OT

**Any further responses from the reviewers can be found at the end of the article**

## Introduction

Liver transplantation (LT) currently remains the only long-term treatment option for patients with end-stage liver failure. The success of LT was enabled by the introduction of effective pharmacological immunosuppressive strategies, which mostly target recipient T lymphocyte responses. The drugs that mediate immunosuppression (IS) in LT recipients exert their effects either by inhibiting intracellular T lymphocyte signalling or cellular proliferation. Calcineurin inhibitors (CNIs)<sup>1</sup> and mammalian target of rapamycin inhibitors (mTOR-I)<sup>2</sup> target the former, whereas corticosteroids<sup>3</sup> or antimetabolites like mycophenolate mofetil<sup>4</sup> or azathioprine<sup>5</sup> impair the latter. Moreover, biologic agents blocking the anti-interleukin 2 receptor on activated T lymphocytes (e.g., basiliximab<sup>6</sup>) or inhibiting T lymphocyte costimulation (preliminary data in kidney transplantation: belatacept<sup>7</sup>) have been developed more recently to reduce CNI exposure.

While providing effective protection against acute and chronic cellular rejection of the allograft, lifelong IS, particularly corticosteroids and CNIs, are known to cause significant side effects<sup>8</sup>. Common side effects include various malignancies, cardiovascular and metabolic diseases, renal toxicity, as well as susceptibility to infections<sup>9–14</sup>. These significant side effects account for chronic morbidity and impair quality of life of LT recipients. Therefore, efforts to minimise exposure to immunosuppressive drugs while preserving graft integrity are warranted.

Among all solid organ transplants (SOT), the transplanted liver exhibits unique immunoregulatory properties, which render liver allografts less dependent on IS<sup>15–17</sup>. The attributed mechanisms of liver allograft tolerance are complex and may include deficient antigen presentation, large antigen load, neutralisation of alloantibodies, regulatory T cell (Treg) generation, and long-term microchimerism<sup>18–22</sup>. Accordingly, LT recipients usually require less intensive IS treatment with lower levels and/or numbers of immunosuppressive drugs compared to other SOT recipients<sup>23</sup>. In addition, human leukocyte antigen (HLA) match requirements between donor and recipient are less stringent, and the incidence and severity of acute cellular rejection (ACR) episodes are lower and usually better tolerated in LT as compared to other SOT recipients<sup>24</sup>.

Based on these particular features, clinical studies that examined IS minimization or even complete IS withdrawal (ISW) in LT recipients have been initiated already in the 1990s<sup>25–28</sup>. Most of these ISW studies (at least all of the recent ones) applied

predefined eligibility criteria such as absence of recent rejection episodes or absence of significant histological lesions in a baseline biopsy<sup>29,30</sup>. In all studies, a significant subset of study participants exhibited stable allograft function and histological graft integrity despite complete ISW<sup>31</sup>. In agreement with the nomenclature used in the literature, we herein call this state of spontaneous immunological transplant tolerance *operational tolerance* (OT)<sup>32</sup>. However, the majority of study participants still would experience an ACR episode or develop abnormal liver function tests following ISW and eventually require the reinstatement of immunosuppressive drugs<sup>31</sup> (ISW failure). The mechanisms underlying ISW success or failure in LT recipients are currently not completely elucidated. Likewise, whether ISW outcomes may be predictable at all (see below) or IS minimisation is a safer alternative to complete ISW is not yet known<sup>33</sup>.

The discovery of OT has promoted extensive research activity over the last two decades<sup>34</sup>. On the one hand, it is important to explore the factors that are associated with or enable the development of OT in a subset of transplant recipients<sup>35</sup>. More detailed knowledge on such predictors of spontaneous OT will help to refine the eligibility criteria for LT recipients to participate in ISW trials and hopefully increase the fraction of successful ISW attempts. On the other hand, researchers have started to address the question as to whether OT can be induced by immune manipulation prior to ISW. Thus, infusion of donor-derived hematopoietic stem cells<sup>36–40</sup>, Treg<sup>41</sup>, regulatory dendritic cells (DCreg)<sup>42</sup> or mesenchymal stem cells<sup>43,44</sup>, as well as lymphodepletion protocols using T lymphocyte-directed antibodies<sup>45</sup> have been or are being tested for their potential to induce tolerance<sup>31</sup>.

## Why it is important to do this review?

Regarding the therapeutic dilemma of deleterious effects of chronic IS vs. the risk of ISW failure and graft injury after LT, there is a medical need to define clinical and biochemical markers to predict the success of ISW. Up to now, there is only one systematic review that addressed the benefits and harms of ISW in LT recipients<sup>46</sup>. It focused on CNI and included only randomized controlled trials (RCTs) comparing ISW and IS continuation after LT. The authors identified a single ongoing RCT, which has been published in the meantime<sup>47</sup>. In this RCT, the non-inferiority analysis of ISW vs. unchanged IS maintenance treatment on a composite morbidity/mortality endpoint was inconclusive. Based on these results and an unpublished scoping search in the literature that did not identify any new RCTs on this comparison, we concluded that there was not enough data for a new systematic review approach comparing ISW and IS continuation after LT.

In contrast, the number of publications that highlight predisposing factors or biomarkers for spontaneous OT in ISW cohorts is increasing<sup>35</sup>. We, therefore, reasoned that the systematic scoping for evidence on such factors would best inform the community regarding the therapeutic dilemma of IS after LT. Accordingly, this scoping review will for the first time systematically collect biomarkers and clinical parameters that are likely predictors of spontaneous OT. The anticipated results shall set the basis for subsequent evidence syntheses or clinical trials with a sharpened research focus. Any evidence

that will help understand the spontaneous development of OT and increase the fraction of successful ISW by enabling an informed preselection of ISW candidates is of great value to the community, as it will provide valuable guidance in the therapeutic dilemma of IS after LT.

### Study aim and objectives/questions

The objective of this scoping review will be to map all published prognostic factors for spontaneous OT in non-viral hepatitis and non-autoimmune disease LT recipients who are undergoing ISW. The obtained results may inform the subsequent conduct of a systematic review with a more targeted review question.

Specifically, the review questions are:

- i) What are clinical parameters and biomarkers that predispose LT recipient ISW candidates to achieve spontaneous OT?
- ii) What are the success rates of ISW and achievement of spontaneous OT in LT recipients?
- iii) What are the rates of graft loss in LT recipients following ISW?

### Protocol

#### Data collection

#### Eligibility criteria

#### Population, Intervention, Outcomes

The primary eligibility criterion will be the assessment of spontaneous OT, i.e. rejection-free liver allograft survival for at least one year following ISW. LT recipients of any age or stage will be included, but recipients with underlying autoimmune diseases, replicative viral disease and/or multi-organ recipients will be excluded. Studies reporting on mixed populations will be included, if less than 20% of the study population has a viral or autoimmune liver disease aetiology. Studies that do not report the liver disease aetiologies for LT in their population will also be included. All pharmacological IS regimens including combination treatments being completely withdrawn will be eligible. However, studies addressing dose reduction of IS including IS minimisation, withdrawal of a subset of drugs from IS combination treatments (e.g. withdrawal of corticosteroids in patients on CNI maintenance treatment), or conversion between IS regimens (e.g. CNI to mTOR-I conversion vs. CNI continuation) will be excluded.

We will include studies that assess an association of pre-ISW clinical parameters or biomarkers on the development of OT. Studies exclusively addressing the effectiveness of induction or immunomodulation therapies for development of OT (using lymphodepletion or infusion with regulatory immune cells) will be excluded. Prespecified pre-ISW clinical parameters potentially predicting OT are sex, recipient age at LT, time since LT, history of episodes of rejection, liver histology, pharmacologic IS regimen, living (LD) or deceased donor (DD) LT, degree of kinship (or HLA match) of the donor, lymphocytotoxic crossmatch, liver disease aetiology, and previous pregnancies, SOT, or blood transfusions. Prespecified pre-ISW biomarkers potentially predicting OT are any up- or downregulated immune cell subsets (detected by flow cytometry or mass cytometry), any up- or downregulated genes or micro RNAs

in the liver allograft or peripheral blood (detected by gene microarray, quantitative PCR, or RNA-seq), epigenetic markers, and anti-HLA antibodies (detected by ELISA, single antigen bead assay, or complement-dependent cytotoxicity assay). Owing to the risk of confounding by interrupted IS in the OT cohort (i.e. featuring successful ISW), data on post-ISW biomarkers will be excluded unless the same biomarkers were measured in the same patients already before ISW.

#### Types of study to be included

We will include prospective, retrospective, randomised, and non-randomised studies irrespective of publication status and including case-control and cross-sectional designs. By reporting on those patients that did not achieve OT after ISW most relevant studies would include a “control cohort” by default. Principal investigators of ongoing studies and conference abstracts will be contacted twice by email for the sharing of their data. Conference abstracts where the data was subsequently published in a peer-reviewed article will be excluded. Animal studies, case reports, case series (i.e. publications where patient histories of exclusively tolerant or non-tolerant ISW-liver recipients are reported<sup>48</sup>), reviews, letters, and editorials will be excluded. No language or publication date restrictions will be applied.

**Identification of relevant literature.** An information specialist (CA-H) will develop the search strategies, which will be reviewed by a second information specialist. Database-specific subject headings and text words (synonyms and word variations) for liver transplantation, ISW, and OT, graft survival, or liver biopsy will be used. We will search the electronic databases Embase via Elsevier, Medline via Ovid, and the Cochrane Central Register of Controlled Trials (CENTRAL). The search string for Embase is provided in **Box 1**. We will also search the study registry clinicaltrials.gov as well as the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) for ongoing studies. All retrieved references will be exported to EndNote X9 and deduplicated.

One reviewer (CA-H) will screen the deduplicated references based on their titles and abstracts. All potentially relevant references will be retrieved in full-text and independently assessed by two reviewers (CA-H, JV). Any disagreements over eligibility will be resolved by consensus. Where necessary, a third review author (SH) will make a final judgement. All judgements at the full-text screening stage will be collected in a standardised MS Excel 2016 form. Articles in foreign languages that none of the review authors is familiar with will be checked for eligibility by other researchers before translation will be considered. Potentially relevant ongoing studies and conference abstracts will only be included if principal investigators will provide us with chartable data that relate to our primary outcomes (see below).

To identify possible additional studies that will escape our electronic database searches, we will screen the bibliographic references and the citations of all included articles that are indexed in Scopus or the Web of Science.

#### Data analysis

**Quality appraisal.** Within the framework of this scoping review, no quality appraisal is planned.

**Box 1. Search strategy for Embase**

((('liver transplantation'/exp OR (OLT OR LTx):ab,ti OR (('liver'/de OR 'liver lobe'/exp OR 'liver disease'/exp OR 'obstructive bile duct disease'/exp OR 'bile duct atresia'/de OR (liver OR hepatic OR hepato\* OR hepatitis OR hepatitis OR intrahepatic OR extrahepatic OR cirrhosis OR cirrhotic OR 'periportal fibrosis' OR jaundice OR icterus OR bilirubinaemia OR cholestasis OR cholestatic OR ((bile OR biliary OR choledoch\*) NEAR/3 (obstruction OR stasis OR occlusion OR stenosis OR stricture OR obliteration OR atresia OR agenesi\*)):ab,ti) AND ('transplantation'/de OR 'organ transplantation'/de OR 'allograft transplantation'/de OR 'orthotopic transplantation'/de OR 'recipient'/exp OR (transplant\* OR Tx OR allotransplant\* OR graft\* OR allograft\* OR recipient\*):ab,ti)))

AND

((('immunosuppressive agent'/exp OR 'calcineurin inhibitor'/exp OR 'mammalian target of rapamycin inhibitor'/de OR 'immunosuppressive treatment'/de) AND ('treatment withdrawal'/exp OR 'weaning'/de)) OR (((immunosuppress\* OR immuno-suppress\* OR immune-suppress\* OR immunodepress\* OR immuno-depress\* OR immune-depress\* OR anti-rejection OR antirejection OR 'immune system-suppressing' OR 'transplantation reaction inhibition' OR anti-metaboli\* OR antimetaboli\* OR azathioprine OR belatacept OR cyclophosphamide OR daclizumab OR 'mycophenolate mofetil' OR MMF OR 'mycophenolic acid' OR cellcept OR 'calcineurin inhibitor\*' OR 'protein phosphatase 2B inhibitor\*' OR cyclosporin\* OR ciclosporin\* OR neoral OR sandim\* OR tacrolimus OR advagraf OR prograf\* OR fk506 OR fk-506 OR 'mammalian target of rapamycin inhibitor\*' OR 'mammalian target of rapamycin kinase inhibitor\*' OR 'mechanistic target of rapamycin inhibitor\*' OR 'mechanistic target of rapamycin kinase inhibitor\*' OR 'mTOR inhibitor\*' OR 'mTOR kinase inhibitor\*' OR everolimus OR rad001\* OR rad-001\* OR rapamune OR rapamycin OR sirolimus) NEAR/4 (withdraw\* OR taper\* OR wean\* OR minimization OR minimisation OR minimizing OR minimising OR sparing OR eliminat\* OR reduction OR reducing OR lower\* OR cessation OR discontinu\* OR interrupt\* OR abstinence OR avoid\* OR stop\* OR downgrad\* OR diminish\* OR free\*)) OR is-withdraw\* OR is-taper\* OR is-wean\* OR is-minimization OR is-minimisation OR is-minimizing OR is-minimising OR is-sparing OR is-eliminat\* OR is-reduction OR is-reducing OR is-lower\* OR is-cessation OR is-discontinuation OR is-interrupt\* OR is-abstinence OR is-avoid\* OR is-stop\* OR is-downgrad\* OR is-diminish\* OR is-free):ab,ti))

AND

('transplantation tolerance'/de OR 'immunological tolerance'/de OR 'immunoregulation'/de OR 'immunoreactivity'/de OR 'graft survival'/de OR 'liver biopsy'/de OR (tolerogen\* OR 'tolerant patient\*' OR 'tolerant state' OR 'state of tolerance' OR 'sustained weaning' OR ((transplant\* OR posttransplant\* OR operational\* OR immune OR immunologic\* OR alloimmune OR allograft\* OR graft\* OR alloantigen\* OR antigen\* OR chimerism OR donor-specific OR peripheral) NEAR/3 (tolerance OR tolerant OR tolerated OR tolerating OR acceptance OR protect\* OR quiescen\* OR unresponsive\* OR nonresponsive\* OR un-responsive\* OR non-responsive\*)) OR immunoregulat\* OR immunosurveill\* OR immunoreactiv\* OR immunoactiv\* OR ((immune OR immunologic\*) NEXT (regulat\* OR surveill\* OR reactiv\* OR activ\*)) OR ((graft OR allograft OR transplant\* OR liver OR hepatic) NEAR/3 (survival OR health OR function OR 'resistance to rejection')) OR ((inhibit\* OR decrease OR abolish OR suppress\* OR reduc\* OR ameliorat\* OR improve\* OR absent OR avoid\* OR prevent\*) NEAR/3 (graft OR allograft OR transplant\* OR liver OR hepatic) NEAR/3 (injury OR complication\* OR dysfunction OR inflammation OR fibrosis OR infiltration)) OR ((inhibit\* OR decrease OR abolish OR suppress\* OR reduc\* OR ameliorat\* OR improve\* OR absent OR avoid\* OR prevent\*) NEAR/3 (rejection OR 'immune response\*' OR 'alloimmune response\*' OR 'T-cell response\*' OR 'B-cell response\*' OR 'antibody response\*' OR 'humoral response\*')) OR ((liver OR hepatic) NEAR/3 (biopsy OR biopsies OR puncture\*)):ab,ti))

NOT

((('animal'/de OR 'animal experiment'/exp OR 'nonhuman'/de) NOT ('human'/exp OR 'human experiment'/de))

**NOTE: The subject heading "graft rejection" (and respective free text terms) was omitted from the third search block, because its tentative inclusion resulted in a non-manageable increase of hits.**

**Data charting.** Next to reported prognostic and non-prognostic factors (clinical parameters and biomarkers) for OT, which will be the primary outcomes, we will also chart the percentage of successful ISW and achievement of sustained OT and the rate of graft loss in each trial as the secondary outcomes. Two reviewers (CA-H, JV) will independently chart the data from each eligible article using a jointly developed MS Excel 2016 charting form that will be pilot tested using four eligible full-text articles. If necessary, the charting form will be updated in an iterative process. Any disagreements will be solved by discussion. Data will be sought for the following variables:

- Article characteristics such as first author, year of publication, country of origin, and bibliographic details
- Funder
- Trial ID
- Mono- or multicenter study
- Study design, IS maintenance control group yes/no
- DD and/or LD LT
- Recipient age at LT
- Donor age
- Liver disease aetiology
- Time from LT to ISW
- Duration of follow-up
- IS drug(s)
- ISW schedule
- Method(s) for assessing OT
- Total number of patients that are included in the prognostic analyses
- Percentage of successful ISW (achievement of OT)
- Percentage of graft loss
- Biomarkers predicting OT
- Clinical parameters predicting OT
- Numerical evidence for positive associations
- Biomarkers explicitly not predicting OT
- Clinical parameters explicitly not predicting OT

**Strategy for data synthesis and presentation.** For each included article, ongoing study, or conference abstract with data, we will present the charted data in a “results of individual sources of evidence” table. For the synthesis of collated prognostic factors (biomarkers and clinical parameters) for OT, we will use descriptive statistics showing the individual sources of evidence that support each factor. In addition to a tabular view, the results will be narratively synthesized in the review text. Together, these results will provide a comprehensive scope of past research activity on this topic and likely identify promising future research avenues.

### Design and reporting guidelines

This scoping review will be conducted along with the guidelines by the Joanna Briggs Institute<sup>49</sup> and reported according to the “Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews” (PRISMA-ScR) statement<sup>50</sup>.

### Dissemination of results

The completed review will be published in a peer-reviewed journal.

### Study status

Start date of search: July 2019; anticipated completion date of review: May 2020.

Current study status: preliminary searches, yes; piloting of the study selection process, yes; formal screening of search results against eligibility criteria, started; data extraction, no; data analysis, no.

### Conclusions

Since the first reports of spontaneous OT in LT<sup>25–28</sup>, numerous studies of ISW have been published (reviewed in 32). These studies were initially uncontrolled and heterogeneous in their design, rendering any comparison between them and any conclusions difficult to draw. Following the creation of international consortia (Immune Tolerance Network – ITN – in the US and Reprogramming the Immune System for the Establishment of Tolerance – RISE – in Europe), inclusion/exclusion criteria of ISW studies in LT have been harmonised, thus allowing cross-comparisons and cross-validations between studies. For instance, two ongoing multicenter trials (LIFT<sup>51</sup> and OPTIMAL<sup>52</sup>) share the same inclusion/exclusion criteria.

These ISW trials have in parallel fuelled the need to find reliable biomarkers for the identification of those patients who are more likely to successfully stop IS, a problem that is most critical for the safety and future applicability of ISW. While clinically not available yet, several biomarkers have already been evaluated in LT recipients. In this scoping review, we will map all information on this body of literature. In addition to that, our searches in clinical trial registries will provide an overview of the current research activity in the field. The anticipated results will allow us to determine possible research gaps and whether any future systematic reviewing and meta-analysis efforts are warranted.

### Data availability

#### Underlying data

No data are associated with this article.

### References

- Haddad EM, McAlister VC, Renouf E, *et al.*: **Cyclosporin versus tacrolimus for liver transplanted patients.** *Cochrane Database Syst Rev.* 2006; (4): CD005161. [PubMed Abstract](#) | [Publisher Full Text](#)
- Touzot M, Soullou JP, Dantal J: **Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use.** *Curr Opin Organ Transplant.* 2012; 17(6): 626–33. [PubMed Abstract](#) | [Publisher Full Text](#)
- Al-Sinani S, Dhawan A: **Corticosteroids usage in pediatric liver transplantation: To be or not to be!** *Pediatr Transplant.* 2009; 13(2): 160–70. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kaltenborn A, Schrem H: **Mycophenolate mofetil in liver transplantation: a review.** *Ann Transplant.* 2013; 18(1): 685–96. [PubMed Abstract](#) | [Publisher Full Text](#)
- Germani G, Pleguezuelo M, Villamil F, *et al.*: **Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil.** *Am J Transplant.* 2009; 9(8): 1725–31. [PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang GQ, Zhang CS, Sun N, *et al.*: **Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.** *Hepatobiliary Pancreat Dis Int.* 2017; 16(2): 139–46. [PubMed Abstract](#) | [Publisher Full Text](#)
- Perez CP, Patel N, Mardis CR, *et al.*: **Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types.** *Transplantation.* 2018; 102(9): 1440–52. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gelson W, Hoare M, Dawwas MF, *et al.*: **The pattern of late mortality in liver transplant recipients in the United Kingdom.** *Transplantation.* 2011; 91(11): 1240–4. [PubMed Abstract](#) | [Publisher Full Text](#)
- Campbell KM, Yazigi N, Ryckman FC, *et al.*: **High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation.** *J Pediatr.* 2006; 148(4): 475–80. [PubMed Abstract](#) | [Publisher Full Text](#)
- Green M, Michaels MG: **Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.** *Am J Transplant.* 2013; 13 Suppl 3: 41–54; quiz. [PubMed Abstract](#) | [Publisher Full Text](#)
- Henchoz S, Fraga M, Saouli AC, *et al.*: **[Outpatient follow-up of liver transplant recipients: the essential role of the general practitioner].** *Rev Med Suisse.* 2019; 15(660): 1488–95. [PubMed Abstract](#)
- Jain A, Mazariegos G, Kashyap R, *et al.*: **Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.** *Transplantation.* 2000; 70(4): 617–25. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ng VL, Fecteau A, Shepherd R, *et al.*: **Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a north american multicenter registry.** *Pediatrics.* 2008; 122(6): e1128–35. [PubMed Abstract](#) | [Publisher Full Text](#)
- Venick RS: **What is the future of pediatric liver transplantation? Optimal management of long-term recipients.** *Liver transpl.* 2014; 20 Suppl 2: S19–21. [PubMed Abstract](#) | [Publisher Full Text](#)
- Demetris AJ, Bellamy CO, Gandhi CR, *et al.*: **Functional Immune Anatomy of the Liver-As an Allograft.** *Am J Transplant.* 2016; 16(6): 1653–80. [PubMed Abstract](#) | [Publisher Full Text](#)
- Heymann F, Tacke F: **Immunology in the liver—from homeostasis to disease.** *Nat Rev Gastroenterol Hepatol.* 2016; 13(2): 88–110. [PubMed Abstract](#) | [Publisher Full Text](#)
- Londoño MC, Rimola A, O’Grady J, *et al.*: **Immunosuppression minimization**

- vs. complete drug withdrawal in liver transplantation. *J Hepatol.* 2013; **59**(4): 872–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Pender MP: **Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance.** *Immunol Cell Biol.* 1999; **77**(3): 216–23.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  19. Thomson AW, Knolle PA: **Antigen-presenting cell function in the tolerogenic liver environment.** *Nat Rev Immunol.* 2010; **10**(11): 753–66.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  20. Crispe IN: **Immune tolerance in liver disease.** *Hepatology.* 2014; **60**(6): 2109–17.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  21. Jenne CN, Kubes P: **Immune surveillance by the liver.** *Nat Immunol.* 2013; **14**(10): 996–1006.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  22. Starzl TE, Demetris AJ, Trucco M, et al.: **Systemic chimerism in human female recipients of male livers.** *Lancet.* 1992; **340**(8824): 876–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  23. Calne RY: **Immunological tolerance—the liver effect.** *Immunol Rev.* 2000; **174**(1): 280–2.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  24. Navarro V, Herrine S, Katopes C, et al.: **The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database.** *Liver Transpl.* 2006; **12**(4): 652–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  25. Starzl TE, Demetris AJ, Trucco M, et al.: **Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.** *Hepatology.* 1993; **17**(6): 1127–52.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  26. Tzakis AG, Reyes J, Zeevi A, et al.: **Early tolerance in pediatric liver allograft recipients.** *J Pediatr Surg.* 1994; **29**(6): 754–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  27. Ramos HC, Reyes J, Abu-Elmagd K, et al.: **Weaning of immunosuppression in long-term liver transplant recipients.** *Transplantation.* 1995; **59**(2): 212–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  28. Mazariegos GV, Reyes J, Marino IR, et al.: **Weaning of immunosuppression in liver transplant recipients.** *Transplantation.* 1997; **63**(2): 243–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  29. Feng S, Ekong UD, Lobritto SJ, et al.: **Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants.** *JAMA.* 2012; **307**(3): 283–93.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  30. Benítez C, Londoño MC, Miquel R, et al.: **Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients.** *Hepatology.* 2013; **58**(5): 1824–35.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  31. Levitsky J, Feng S: **Tolerance in clinical liver transplantation.** *Hum Immunol.* 2018; **79**(5): 283–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  32. Feng S, Bucuvalas J: **Tolerance after liver transplantation: Where are we?** *Liver Transpl.* 2017; **23**(12): 1601–14.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  33. Porrett P, Shaked A: **The failure of immunosuppression withdrawal: patient benefit is not detectable, inducible, or reproducible.** *Liver Transpl.* 2011; **17 Suppl 3**: S66–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  34. Mathew JM, Leventhal JR: **Clinical transplant tolerance: Coming of age.** *Hum Immunol.* 2018; **79**(5): 255–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  35. Vionnet J, Sánchez-Fueyo A: **Biomarkers of immune tolerance in liver transplantation.** *Hum Immunol.* 2018; **79**(5): 388–94.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  36. Donckier V, Troisi R, Toungouz M, et al.: **Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.** *Transpl Immunol.* 2004; **13**(2): 139–46.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  37. Tryphonopoulos P, Ruiz P, Wepler D, et al.: **Long-term follow-up of 23 operational tolerant liver transplant recipients.** *Transplantation.* 2010; **90**(12): 1556–61.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  38. Donckier V, Craciun L, Lucidi V, et al.: **Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells.** *Transplantation.* 2009; **87**(9 Suppl): S91–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  39. Tryphonopoulos P, Tzakis AG, Wepler D, et al.: **The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation.** *Am J Transplant.* 2005; **5**(3): 608–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  40. Donckier V, Troisi R, Le Moine A, et al.: **Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion.** *Liver Transpl.* 2006; **12**(10): 1523–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  41. Todo S, Yamashita K, Goto R, et al.: **A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation.** *Hepatology.* 2016; **64**(2): 632–43.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  42. Thomson AW: **DCreg in Living Donor Liver Transplantation.** <https://ClinicalTrials.gov>; 2017 [updated August 30].  
[Reference Source](#)
  43. Detry O, Vandermeulen M, Delbouille MH, et al.: **Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.** *J Hepatol.* 2017; **67**(1): 47–55.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  44. Sturm E, Hartleif S: **Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation.** <https://ClinicalTrials.gov>; 2017 [updated March 10].  
[Reference Source](#)
  45. Benítez CE, Puig-Pey I, López M, et al.: **ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation.** *Am J Transplant.* 2010; **10**(10): 2296–304.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  46. Penninga L, Wettergren A, Chan AW, et al.: **Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.** *Cochrane Database Syst Rev.* 2012; (3): CD008852.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  47. Shaked A, DesMarais MR, Kopetskie H, et al.: **Outcomes of immunosuppression minimization and withdrawal early after liver transplantation.** *Am J Transplant.* 2019; **19**(5): 1397–409.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  48. Dekkers OM, Egger M, Altman DG, et al.: **Distinguishing case series from cohort studies.** *Ann Intern Med.* 2012; **156**(1 Pt 1): 37–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  49. Peters MD, Godfrey CM, Khalil H, et al.: **Guidance for conducting systematic scoping reviews.** *Int J Evid Based Healthc.* 2015; **13**(3): 141–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  50. Tricco AC, Lillie E, Zarin W, et al.: **PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.** *Ann Intern Med.* 2018; **169**(7): 467–73.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  51. Sanchez-Fueyo A: **Liver Immunosuppression Free Trial.** <https://ClinicalTrials.gov>; 2015 [updated October].  
[Reference Source](#)
  52. Markmann JF: **Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation.** <https://ClinicalTrials.gov>; 2016 [updated January 6].  
[Reference Source](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 22 April 2020

<https://doi.org/10.5256/f1000research.24506.r61649>

© 2020 Czubkowski P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Piotr Czubkowski** 

Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland

The Authors performed the scoping review clarifying the ways of obtaining and analyzing data on operational tolerance in liver transplant recipients, both adults and children. The aim of this comprehensive review is to identify prognostic factors, clinical parameters and biomarkers, for spontaneous operational tolerance after complete immunosuppression withdrawal. This is extremely interesting topic from scientific point of view but even more then that it has high relevance from patient's perspective, especially children for whom lifetime immunosuppression is significant burden. Nevertheless, this task requires high quality data, clear inclusion criteria and cautious interpretation.

1. Do the Authors plan to pool adult and pediatric data together or review it separately? Interpolation of adult data for children should be avoided.
2. Eliminating autoimmune or viral etiologies may cause selection bias – what was the rationale for this criterion? If manuscripts with unknown etiology or less then 20% of autoimmune/viral are eligible for the study, this criterion should be more clarified or maybe just simplified.
3. I'd be cautious in adding conference abstracts, or maybe the Authors should exclude abstracts older then 2-3 years which were not published so far or direct contact with the Authors of conference abstracts should be considered for data clarification and update.

In terms of study aims/objectives:

1. Success rate of ISW: how the Authors plan to define the outcomes, regarded different efficacy endpoints among the studies (minimum period of follow-up without rejection, protocol liver biopsy)?

**Is the rationale for, and objectives of, the study clearly described?**

Yes

**Is the study design appropriate for the research question?**

Partly



**Are sufficient details of the methods provided to allow replication by others?**

Yes

**Are the datasets clearly presented in a useable and accessible format?**

Not applicable

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Pediatric hepatology and liver transplantation

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 07 February 2020

<https://doi.org/10.5256/f1000research.24506.r59244>

© 2020 Kelly D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Deirdre Kelly**

Liver Unit, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK

**Is the rationale for, and objectives of, the study clearly described?**

Not applicable

**Is the study design appropriate for the research question?**

Not applicable

**Are sufficient details of the methods provided to allow replication by others?**

Not applicable

**Are the datasets clearly presented in a useable and accessible format?**

Not applicable

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

Version 1

Reviewer Report 13 January 2020

<https://doi.org/10.5256/f1000research.23689.r57506>

© 2020 Kelly D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Deirdre Kelly

Liver Unit, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK

This scoping review systematically sets out how the Authors will consider studies that will record clinical details or biomarkers of relevance in the initiation of immunosuppression withdrawal. It is an ambitious review and although the Authors have laid out their strategy quite clearly by searching the relevant registries, databases and publications they do not specify whether they will include studies in children as well as adults. Most of the references are adult studies, so presumably this is the focus. I think the Authors will need to differentiate between IS minimisation or complete IS withdrawal and be clear which definitions they will include in their review for analysis..

With regard to the review questions:

- The clinical parameters and biomarkers (Question 1) may be difficult to clearly identify whereas review questions 2 and 3 are more likely to be clearly defined in studies and databases.

The relevance of this review and its potential benefit to patients is obvious, I am concerned that it will require an extensive amount of work without identifying a clear outcome of value to Clinicians or Patients.

#### **Is the rationale for, and objectives of, the study clearly described?**

Yes

#### **Is the study design appropriate for the research question?**

No

#### **Are sufficient details of the methods provided to allow replication by others?**

Yes

#### **Are the datasets clearly presented in a useable and accessible format?**

Not applicable

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 27 Jan 2020

**Christian Appenzeller-Herzog**, University of Basel, Basel, Switzerland

Dear Prof. Kelly,

Thank you very much for your constructive reviewer report and for drawing our attention to different

issues in our protocol and possibilities for improvement. We are most happy with your judgements that this ambitious review has an obvious potential benefit to patients and that our protocol paper is of an acceptable scientific standard. With regard to your criticism, we would like to address the three points you raised: i) pediatric or adult patients?, ii) IS withdrawal and minimisation?, iii) difficulties to cope with review question 1:

- Pediatric/adult: This review will include all ISW studies irrespective of LT recipient age. Our protocol already states in the subsection “population, intervention, outcomes” that “LT recipients of any age or stage will be included”. To make this clearer to the reader we have now also added this information in the abstract, which now reads: “We will consider studies that record any clinical parameter or biomarker before the initiation of ISW in paediatric or adult non-viral hepatitis and non-autoimmune disease LT recipients ...”

The question whether or not OT-predicting factors differ in children and adults is interesting and important. Potentially, the planned systematic mapping of published predicting factors could provide some clues on this in the final review.

- IS withdrawal/minimisation: This review will only focus on full ISW studies and exclude studies on IS minimisation. Our protocol already holds the following statement in the subsection “population, intervention, outcomes”: “However, studies addressing dose reduction of IS, (...) will be excluded”. To clarify that also IS minimization studies will be considered ineligible we have now implemented the following extension: “However, studies addressing dose reduction of IS including IS minimisation, (...) will be excluded”.
- Review question 1: This is an important issue and we thank you for pointing this out. The objective of this scoping review is to collect and map all available evidence of OT-predicting factors. If no such factors can be identified, this result, albeit negative, will still be of importance and worth reporting. However, as you are pointing out, the formulations in our protocol are implying that our aim is to “identify” such factors in the literature. Instead, we should state that our objective is the mapping of all available evidence on such factors. In response to this important point of criticism, we have implemented the following revisions: Abstract: “This scoping review aims at systematically mapping reported prognostic factors for spontaneous immunosuppression (IS) free allograft tolerance (operational tolerance, OT) in non-viral hepatitis and non-autoimmune disease liver transplant (LT) recipients who are undergoing immunosuppression withdrawal (ISW).” Study aim and objectives/questions: “The objective of this scoping review will be to map all published prognostic factors for spontaneous OT in non-viral hepatitis and non-autoimmune disease LT recipients who are undergoing ISW.”

We sincerely hope that these amendments to our protocol will help convince you to fully approve the revised version of our manuscript. Thank you again for your invaluable help in this matter.

Christian Appenzeller-Herzog, Steffen Hartleif, Julien Vionnet

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**